Pharmaniaga Bhd (XKLS:7081) ROCE %: 35.14% (As of Mar. 2026)


XKLS:7081 Pharmaniaga Bhd XKLS:7081
46 GF Score
Price RM1.22
GF Value RM0.74
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Pharmaniaga Bhd ROCE %?

Pharmaniaga Bhd XKLS:7081 -4.69% 46 ROCE % is 35.14% as of Mar. 2026. GuruFocus rates XKLS:7081 with a GF Score™ of 46/100 and a GF Value™ of RM0.74 (Significantly Overvalued). The stock has 8 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Pharmaniaga Bhd's annualized ROCE % for the quarter that ended in Mar. 2026 was 35.14%.

Pharmaniaga Bhd  (XKLS:7081) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Pharmaniaga Bhd ROCE % Related Terms

Pharmaniaga Bhd ROCE % Historical Data

* Premium members only.

The historical data trend for Pharmaniaga Bhd's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmaniaga Bhd ROCE % Chart

Pharmaniaga Bhd Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 52.77 -200.31 0.00 0.00 40.32

Pharmaniaga Bhd Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 678.55 280.68 29.74 14.84 35.14
XKLS:7081
46GF Score
Pharmaniaga Bhd XKLS:7081
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmaniaga Bhd ROCE % Calculation

Pharmaniaga Bhd's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=136.082/( ( (1992.306 - 1953.073) + (2246.827 - 1611.087) )/ 2 )
=136.082/( (39.233+635.74)/ 2 )
=136.082/337.4865
=40.32 %

Pharmaniaga Bhd's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=225.968/( ( (2246.827 - 1611.087) + (2357.398 - 1706.929) )/ 2 )
=225.968/( ( 635.74 + 650.469 )/ 2 )
=225.968/643.1045
=35.14 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 35.14% mean?
Pharmaniaga Bhd (XKLS:7081) has a ROCE % of 35.14% as of Mar. 2026.
Is Pharmaniaga Bhd's ROCE % too high?
Pharmaniaga Bhd's current ROCE % is 35.14%. The Medical Distribution industry median ROCE % is 8.92. Pharmaniaga Bhd's value of 35.14% is 293.9% above this industry median. Overall, Pharmaniaga Bhd has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmaniaga Bhd's ROCE % compare to MCK and CAH?
Pharmaniaga Bhd's ROCE % of 35.14% can be compared against companies in the Medical Distribution industry. The industry median ROCE % is 8.92. Pharmaniaga Bhd's value of 35.14% is 293.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Distribution company?
The median ROCE % among Medical Distribution companies is 8.92, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmaniaga Bhd's current ROCE % of 35.14% is 293.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median ROCE % is 8.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmaniaga Bhd's current ROCE % is 35.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaniaga Bhd stock overvalued right now?
Based on GuruFocus' analysis, Pharmaniaga Bhd (XKLS:7081) is currently considered Significantly Overvalued. The stock's GF Value™ is RM0.74, compared to a current price of RM1.22 — trading 64.9% above its estimated fair value. The current ROCE % is 35.14% and 293.9% above the Medical Distribution industry median of 8.92. Pharmaniaga Bhd's overall GF Score™ is 46/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Pharmaniaga Bhd (XKLS:7081), the current ROCE % is 35.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmaniaga Bhd (XKLS:7081) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmaniaga Bhd stock appears to be overvalued. The current stock price of RM1.22 is trading 64.9% above its estimated GF Value™ of RM0.74. GuruFocus considers Pharmaniaga Bhd to be Significantly Overvalued.

Key valuation signals for XKLS:7081:

  • ROCE %: 35.14%
  • GF Value™: RM0.74 vs. price of RM1.22 (64.9% above fair value)
  • GF Score™: 46/100 with 8 warning signs
  • Industry Position: 293.9% above the Medical Distribution median

No single metric tells the full story. See the XKLS:7081 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmaniaga Bhd Business Description

Address No. 7, Lorong Keluli 1B, Kawasan Perindustrian Bukit Raja, Seksyen 7, Selatan, Shah Alam, SGR, MYS, 40000
Pharmaniaga Bhd is engaged in the manufacture of pharmaceuticals and medical devices. The company is also involved in logistics and distribution. The group operates in three segments - Logistics and distribution, Manufacturing in Malaysia, and Manufacturing and distribution in Indonesia. Maximum revenue is generated by the logistics and distribution segment in Malaysia. The Logistics and distribution segment is engaged in distribution, trading and wholesaling of pharmaceutical and medical products as well as supply and installation of medical and hospital equipment in Malaysia.
46GF Score

Get the complete analysis for XKLS:7081

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

RM1.22
Price
RM0.74
GF Value